Physician profile
Ashley Muse
NPI 1104599554
$1,866.31
in general payments reported to CMS, 2019-2025
25 companies · $26.70 in 2025
The $26.70 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.18 · 2022: $304 · 2023: $1,439 · 2024: $68.05 · 2025: $26.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.48 | 2023 | |
| Glaxosmithkline, LLC. | $262.96 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $213.92 | 2022-2023 | |
| Lilly USA, LLC | $176.76 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Sumitomo Pharma America, INC. | $145.67 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.19 | 2022-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $83.77 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $81.81 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $64.57 | 2022 | |
| Abbott Laboratories | $62.49 | 2022-2023 | Freestyle Libre 2 |
| Mylan Specialty L.P. | $55.62 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.40 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $35.27 | 2023 | |
| Amgen INC. | $31.10 | 2022-2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $29.91 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.09 | 2022-2023 | Breztri |
| Astellas Pharma US INC | $28.18 | 2021 | |
| Revance Therapeutics, INC. | $26.70 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $25.22 | 2023 | |
| Xeris Pharmaceuticals, INC. | $17.49 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $15.84 | 2022 | |
| Gilead Sciences, INC. | $15.18 | 2023 | Epclusa |
| Eisai INC. | $14.92 | 2023 | |
| Esperion Therapeutics, INC. | $14.29 | 2023 | Nexletol |
| Shield Therapeutics INC | $13.48 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Muse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.